WeTrials shared a post on LinkedIn:
“We are proud to announce our partnership with GenomOncology and Belay Diagnostics to accelerate clinical trial enrollment for CNS cancer patients.
Through our partnership, users can move directly from genomic reports to the WeTrials platform to access a patient-friendly, simplified clinical trial interface aligned with a patient’s biomarker profile and pursue enrollment through a streamlined process.
In this way, molecular insights lead to meaningful treatment opportunities-helping connect patients to innovative therapies and trials, while giving clinicians a seamless on-ramp to patient enrollment directly within their workflow.
Read more about the partnership.”
More posts from WeTrials on OncoDaily.